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INTRODUCTION 
2 
Dental treatment of pediatric patients can be a challenge for dentists, particularly 
for children below the age of 5 years. On occasion, the dentist needs to sedate a child 
patient in order to render dental treatment. Over the years, a variety of sedative agents 
and a variety of means of delivery have been used to sedate children for dental treatinent 
with a range of success. The opiates have been a favored class of sedative medications to 
consciously sedate children and adults for dental treatment. While the opiates work well 
to sedate children, they also carry the unwanted side effect of respiratory depression. 
Meperidine has been used widely in the medical and dental field for sedation of 
patients for years. Meperidine has been studied extensively for its efficacy in sedating 
pediatric dental patients. Butorphanol is also an opiate with sedating qualities and causes 
less respiratory depression than meperidine. Apparently, butorphanol has not been 
studied as a sedative medication for pediatric dental patients. 
The hypothesis of the thesis is that intramuscular butorphanol will have equal or 
better quality as a sedative while displaying the same or fewer physiological effects on 
pediatric dental patients than intramuscular meperidine. 
The null hypothesis is that intramuscular meperidine would provide a better level 
of sedation than an equipotent dosage of intramuscular butorphanol and produce fewer 
physiological effects on the patient. 
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REVIEW OF LITERATURE 
4 
Meperidine hydrochloride is a synthetic narcotic analgesic with actions similar to 
morphine. Meperidine hydrochloride's trade name is Demerol (Sanofi Winthrop ). 1 The 
main therapeutic uses in the dental profession are for analgesia and sedation. Meperidine 
is an opiate agonist at both the mu and kappa opiate receptors with its effects at the mu 
receptor being responsible for sedation, analgesia, respiratory depression, and physical 
dependence. 2 Meperidine is contraindicated in individuals receiving monoamine oxidase 
inhibitors, patients with a history of head injury or increased intracranial pressure, 
patients with compromised respiratory function or low Sa02, patients with severe 
hypotension, and in patients who are pregnant or breast-feeding. 1 Its oral effectiveness is 
arc~und one-fourth of its parenteral effectiveness.2 The onset of action is more rapid than 
morphine, and the duration is shorter. Meperidine is approximately eight to 10 times less 
potent than morphine. In addition, it produces less smooth muscle spasm, less 
constipation, and less depression of the cough reflex than equianalgesic doses of 
morphine. When given parenterally at equianalgesic doses, the degree of sedation and 
respiratory depression are the same for both morphine and meperidine. 3 The side effects 
of meperidine are well-documented and may include respiratory depression and arrest, 
nausea, vomiting, constipation, pruritus, and urinary retention. 1 Meperidine is known to 
be the opioid most commonly abused by health professionals.2 According to the US 
Controlled Substances Act of 1970, meperidine is considered a schedule II substance, 
which indicates a high abuse potential with severe psychic or physical dependence 
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liability. 3 
Butorphanol tartrate is a synthetic narcotic analgesic with agonist-antagonist 
actions. Butorphanol's trade name is Stadel (Bristol-Myers Squibb Co.), and it is 
primarily used as a pain reliever and can be used secondarily as a sedation drug (pre-
anesthetic ). 1 Butorphanol is water-soluble. Its metabolism occurs mainly in the liver and 
is excreted primarily in the urine. Its half-life is 2.5 hours. 1 Butorphanol and its major 
metabolites have agonist effects at the kappa-opioid receptors, agonist/antagonist effects 
at the mu-opioid receptors, and agonist effects at the sigma receptor. Butorphanol's 
agonist effects at the kappa receptor are most likely responsible for its sedative qualities, 
while its antagonist effects at the mu receptor and its agonist effects at the sigma receptor 
are responsible for its limited respiratory depression.4 The sedative effects of 
Butorphanol in animals have been described as apathetic sedation. 5 While the sedative 
effects can be very striking, even in very large doses of 0.3-1.0 mg/kg, it does not produce 
a state of anesthesia in humans. 5 The potency is approximately five times that of 
morphine and around 30 to 40 times that of meperidine. One mg ofbutorphanol is equal 
to approximately 40 mg ofmeperidine.2 Butorphanol's antagonist activity at the mu 
receptor is one-fortieth of the activity of naloxone at that receptor.4 Peak oral absorption 
is 1.5 hours, but only 17 percent of the drug is biologically available after first-pass liver 
metabolism.6 In order to reach clinical efficacy the oral dose must be 4 to 5 times higher 
than the intramuscular (I.M.) or intravenous (I. V.) dosage. 6 The onset of analgesia is 30 
minutes or less following intramuscular administration with a duration of action of 3 to 4 
hours. 1 Adverse reactions include somnolence ( 43 percent), dizziness (19 percent), and 
nausea or vomiting (13 percent). 1 Central nervous system excitation rarely occurs (1 to 2 
6 
percent) and has been described as euphoria, dysphoria, hallucination, disorientation, 
confusion, agitation, and unusual dreams. 6 Butorphanol produces less nausea and 
vomiting than meperidine or morphine.7 The "frozen chest" syndrotne, known to occur 
with fentanyl, has not been observed with butorphanol.6 Physiologic cardiac effects 
include increased pulmonary wedge pressure, increased pulmonary artery pressure, 
increased left ventricular end-diastolic pressure, increased systemic arterial pressure, 
increased pulmonary vascular resistance, increased cardiac index, and increased cardiac 
work.4 Butorphanol appears to be chemically and physically compatible in the same 
solution with atropine, hydroxyzine, and promethazine. 6 Overdose has not been a clinical 
problem with butorphanol, because it has an outstanding history for safety and a low 
abuse record.4' 8 Butorphanol is a controlled substance as a schedule IV medication.3 
A majority of clinical studies on butorphanol have been on adults. In a 1976 study 
by .Tavakoli et al. in which I.M. butorphanol was compared with equianalgesic doses of 
I.M. morphine, butorphanol was found to be safe and effective with minimal side effects.9 
In a 1977 study by Lippmann et al. again comparing I.M. butorphanol with I.M. 
morphine, it was found that butorphanol was rated 94 percent effective or partially 
effective, and drowsiness was the major side effect in 88 percent of the patients. 10 When 
I.M. meperidine and I.M. butorphanol were compared in a 1976 study by Gilbert et al., it 
was found that a 0.028 mg/kg ofbutorphanol provided relief from moderate to severe 
postsurgical pain in a manner that was statistically indistinguishable from that of 1.14 
mg/kg of meperidine. 11 In treatment of postanesthesia shaking, I. V. butorphanol was 
found to be more effective than LV. meperidine in a 1992 study by Vogelsang and 
Hayes.7 In a 1986 study by Finucane et al., it was found that I.M. butorphanol was 
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comparable to LM. dezocine, another agonist-antagonist opiate, for postoperative pain. 12 
Intravenous Butorphanol was found to be similar in sedative properties when compared 
with LV. midazolam. In a 1991 study by Dershwitz et al., using LV. dosages of0.007 
mg/kg, 0.022 mg/kg, and 0.071 mg/kg ofbutorphanol, it was found that significant 
sedation could occur at doses less than those usually needed for analgesia without patient 
amnesia or impaim1ent of psychomotor function. 13 The clinical studies show a wealth of 
information ofbutorphanol use in human adults with a favorable side-effect profile. 
There are very few studies that evaluate butorphanol in pediatric patients. In a 
1988 study by Steg ofLM. butorphanol for treatment of postoperative orthopedic pain in 
adolescents using a mean dosage of0.044 mg/kg, 89 percent of the patients had good to 
excellent pain relief. 14 A 1995 study by Splinter et al. that compared LV. butorphanol at 
0.03 mg/kg 'Nith LV. morphine at 0.15 mg/kg in children (mean age ----5 years old) found 
th~t butorphanol reduced vomiting by 50 percent without an increase in adverse events, 
when given during the operative period for postoperative pain. 15 A 1994 study by 
Lawhorn and Brown, comparing a combination ofbutorphanol 0.04 mg/kg and morphine 
0.08 mg/kg with morphine 0.08 mg/kg only for epidural anesthesia in children, found a 
decrease in the incidence of side effects without a decrease in analgesia. 16 In another 
study by the same primary author in 1994 comparing children (mean age----7.6 years old) 
undergoing dorsal rhizotomy, who were given epidural butorphanol and morphine or 
morphine alone in the above dosages, it was found that the butorphanoVmorphine group 
had a significantly reduced incidence of nausea, vomiting, and pruritus. 17 In a 1981 study 
it was found that intramuscular butorphanol in doses ranging from 0.01-0.02 mg/kg to be 
safe and effective (1 00-percent pain relief for a minimum of one hour) in treating 
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postoperative pain in children (mean age,..., 7.9 years old). 6 However, there has been 
extensive pediatric experience with butorphanol in the Riley Children's Hospital recovery 
room, where it has been used intravenously for over six years for postoperative analgesia. 
The drug is also used on a daily basis in the Riley cardiac catheterization laboratory as a 
sedative analgesic. In these settings, butorphanol has been found to be safe and effective 
when administered to pediatric patients. 
Butorphanol and meperidine are both capable of causing respiratory depression, 
but butorphanol exhibits a ceiling effect. Increasing the dose will lower minute 
ventilation to a point, but further increases result in no further decrease in minute 
ventilation; the increases will only lengthen the duration of the respiratory depression.4 
Butorphanol has an excellent safety record and a large quantity of clinical experience. 5 
Naloxone (Narcan) is a potent antagonist capable of reversing the effects of both 
meperidine and butorphanol. 1 
Both drugs are capable of causing nausea and vomiting, because they have a direct 
effect on the chemoreceptor zone, but this may also be related to the dosage 
administered. 18 The maximum I.M. recommended dose ofDemerol according to the 
1996 Physician's Drug Reference (PDR) is 2.2 mg/kg, up to a total dose of 100 mg. 1 
McKee et al., in studying dose responsiveness to meperidine, found that it was effective 
as a sedative at 0.5 mg/lb and at 1.0 mg/lb, but the incidence of nausea and vomiting was 
higher at the 1.0 mg/lb dose. 19 Butorphanol's propensity for causing nausea and vomiting 
appears to be also dose-related. 11 In the previously mentioned adult study by Gilbert et 
al., utilizing butorphanol intramuscularly, it was found that nausea occurred 
predominantly at the highest dose, approximately 0.057 mg/kg. 11 
9 
Meperidine is usually reser-Ved for the dental patient with extreme fear-related or 
stubborn-defiant behavior. Various forms and combinations of meperidine use have been 
studied with varying success rates. In the previously mentioned study by McKee et al., 
using varying doses of intramuscular meperidine for pediatric dental patients, it was 
found that 80 percent of the 0.5 mg/lb patients and 73 percent of the 1.0 mg/lb patients 
were rated as having good to excellent sedation on the global rating scale. 19 In a 1993 
study of emergency room pediatric patients ( ....... average of 4 years old), the patients 
received 2.0 mg/kg of meperidine and 1.0 mg/kg of promethazine with or without 1.0 
mg/kg of chloropromazine.20 It was found that 74.4 percent of the group with 
chloropromazine was rated moderately to well-sedated, while 65 percent of the group 
without chloropromazine was rated moderately to well-sedated. In a 1992 study by 
Roberts et al., it was found that 2.2 mg/kg of meperidine and 1.1 mg/kg of promethazine 
given orally to moderately uncooperative pediatric dental patients was successful 58 
perce~t of the time in modifying behavior?1 Good sedation was found in 45 percent of 
pediatric dental patients that received 2.0 mg/kg of meperidine and 0.5 mg/kg of 
promethazine orally in a 1993 study by Alfonzo-Echeverri et a1.22 A range of efficacy for 
sedation for dental treatment with meperidine can be determined from the previously 
mentioned studies. 
Nitrous oxide has been used in dentistry since 1844.23 When used in conjunction 
with oxygen, it can effectively and safely provide mild sedation and reduce dental 
anxiety. The absorption of nitrous oxide is through the alveoli and its clinical effects are 
rapid. It is not metabolized and is excreted through the lungs at a rate similar to its 
absorption. One-hundred-percent oxygen is usually administered at the completion of 
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dental procedures to prevent nausea and diffusion hypoxia associated with the nitrous 
oxide.24 The incidence of nausea and vomiting related to nitrous oxide is low and does 
not appear to be related to the concentration (below 50 percent), duration, patient age, or 
patient health status?5 The main reported disadvantage of nitrous oxide is its effect on 
the reproductive system in individuals chronically exposed to high levels of the gas. This 
finding was discovered through studies of those dentists and dental assistants who were 
exposed to nitrous oxide. They showed a higher spontaneous abortion rate and a lower 
fertility rate, most likely due to work environments without scavenging systems. 26 The 
added advantage of using oxygen with the nitrous oxide is the ability to keep a sedated 
patient \veil-oxygenated (fail-safe mechanism does not allow oxygen below 30 percent). 
Hasty et al. supplemented their sedated pediatric patients with oxygen and noted a low 
incidence of desaturation (Sa02<96%) during the course of their dental treatment. 27 
Nitr~:ms oxide is used to enhance the effect of the sedative or analgesic medications. 
Management of the uncooperative child with extensive dental needs may require 
the use of pharmacological agents in those situations where non-pharmacological 
behavior management has been unsuccessful. Behavior management can be especially 
challenging with younger children. In two Swedish studies of three-year-old children 
undergoing first dental visits, negative behavior rates were found to be 32 percent and 11 
percent of the children seen.28 In a 1991 study of Hispanic children by Steelman, it was 
found that 30 percent of three- and four-year-olds undergoing dental treatment were 
unmanageable using standard non-pharmacologic behavior management techniques.29 
Dentists may increase the use of in-office conscious sedation as opposed to the use of 
general anesthesia in the hospital operating room because of the cost increases that 
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general anesthesia would pose to either the patient or the insurance company. In-office 
sedation and general anesthesia have a reportedly favorable mortality and morbidity rate 
of 1:137,000-860,000, compared with the mortality and morbidity of general anesthesia in 
the hospital of 1:1 0,000-19,000.30• 31 
Butorphanol has been evaluated in adult patient populations for sedation for 
dental treatment in several studies. In a 1986 study by Day et al., comparing 
butorphanol/diazepam and fentanyl/diazepam in LV. form for outpatient third molar 
extraction, it was found that the butorphanol/diazepam combination was clinically 
satisfactory and gave a greater degree of conscious sedation in comparison with the 
fentanyl/diazepam combination.32 In a study by Zallen et al. in 1987, a comparison of 
butorphanol/diazepam versus meperidine/diazepam for multiple extractions with LV. 
sedation, it was found that the butorphanol/diazepam combination was superior to the 
mep.erldine/diazepam combination in regard to the diazepam dose required to achieve the 
desired level of sedation, the total diazepam dose, the level of clinical sedation, and in 
patient evaluation parameters.33 In another 1987 study by Abo El Fadl et al., it was 
found that I. V. butorphanol given prior to local anesthesia caused patients receiving 
periodontal surgery to be more stable in their vital signs, show fewer clinical changes, and 
require less time with their surgery when compared with a placebo (sterile saline).34 In a 
1987 study by Mekkey,35 it was shown that, when compared with LV. midazolam in the 
dosage of 0.06 mg/kg given prior to local anesthesia in patients for third molar extraction, 
intravenous butorphanol in the dosage of0.015 mg/kg had good anxiolytic properties 
while maintaining patient consciousness. A 1987 study by J ann et. al. found that 
butorphanol was cEnically effective 74.8 percent of the time with the dosage of 
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approximately 0.02 mg/kg and that sedation occurred in 28.2 percent of the trials,36 when 
it was given intramuscularly to severely and profoundly retarded patients (previously 
refractory to treatment with chloral hydrate) as a premedication for dental treatment. 
Upward dosage titration to an average of 0.04 1ng/kg increased efficacy to 85.0 percent. 
Pediatric dentists have used combinations of oral and I.M. medications for many 
years with varying degrees of success. Two frequently used agents are chloral hydrate 
(Noctec) and meperidine hydrochloride (Demerol). Both of these agents, when used 
properly, can achieve a minimal level of depressed consciousness that does not alter the 
patient's ability to maintain a patent airway independently and respond appropriately to 
verbal commands. 
Some pediatric dentists may be reluctant to use Demerol in their offices due to its 
potential to cause respiratory depression. 1 Chloral hydrate's use has been increasing due 
to its. tehdency to cause less respiratory depression and its high margin of safety. Overall, 
chloral hydrate has an outstanding safety record, but many case reports of mortality and 
morbidity have been reported. These reports include supraventricular and ventricular 
arrhythmias, severe esophageal and gastric irritation with necrosis, life-threatening 
hypotension, respiratory arrest, and even induced laryngospasm and cardiac arrest 
associated with rapid introduction into the oral pharynx with a syringe?3 Chloral 
hydrate's sedative effect cannot be reversed as is possible with a narcotic agent, and there 
is some growing concern in the scientific and medical communities that a metabolite of 
chloral hydrate may be carcinogenic.37'38 Chloral hydrate has been shown in several 
studies with rodents to induce hepatocarcinoma when given in chronic high doses. On 
the other hand, chloral hydrate has shown no clinically significant increase of carcinoma 
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in humans. 38 If the availability of chloral hydrate decreases, there will be a renewed 
interest in other safe and effective sedative agents. 
Physiologic n1onitoring is an important aspect of sedation study methodology in 
order to document drug side effects and patient safety. Pulse oximetry is considered by 
those involved in sedation as the standard for patient monitoring. 39 It is an indirect 
measure of oxygen saturation of the blood and heart rate. Usually oxygen saturation is 
stable during sedations with only an occasional desaturation. Blood pressure is another 
measure that can be obtained with either a manual blood pressure cuff or with an 
automated blood pressure cuff. In conscious sedation dosage ranges, most sedative drugs 
will not cause a significant clinical change in blood pressure. In a 1995 study by 
Croswell et al., electronic monitoring showed 1 0 episodes of confirmed respiratory 
compromise, while traditional monitoring (visual assessment, precordial stethoscope, and 
palpa,tion) only identified three of the same episodes.40 The American Academy of 
Pediatric Dentistry 1997-98 guidelines for conscious sedation recommend that the level 
of patient consciousness, the patient's airway patency, pulse oximetry, heart, and 
respiration rates be monitored throughout the operative period.41 
A child's behavior can vary from one end of the behavior spectrum to the other. 
During a dental appointment, both ends of the behavior spectrum can be displayed, which 
makes rating a child's behavior a difficult undertaking. A child's behavior can be assessed 
through several different means and times. A child can be evaluated by parent interview 
before the appointment using the Eyeberg Child Behavior Inventory. However, in a 1994 
study by Dunegan et al., the inventory was shown to be a poor predictor of disruptive or 
cooperative behavior within the dental setting.42 In a 1993 study by Lochary et. al., it was 
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found that the Toddler Temperament Scale predicted struggling behavior during sedation 
from children with the approach/withdrawal tendency.43 A similar finding was 
reproduced in a 1994 study by Radis et al., in which approach/withdrawal and 
adaptability could predict quiet behavior in three-year-old patients undergoing initial 
dental exams.44 In a 1994 study by Sanders et al., it was found that a well-rested child 
preoperatively is associated with a more successful sedation with chloral hydrate and 
hydroxyzine.45 While these instruments have their place, intraoperative evaluation of 
behavior has been the gold standard of rating the efficacy of sedation drugs in the dental 
setting. 
Any study of anxious behavior of the patient in the dental setting should include 
subjective self-report measures, physiological measures, and behavioral measures.46 
While the information gained from adults' self-reports can be valuable, in young children 
( <5 years old) it is hard to obtain accurate information due to the lack of verbal skills and 
comprehension. Physiologic parameters are of utmost importance to measure the side 
effects of sedative medications and the physical status of the patient, but such parameters 
are of little value in measuring patient anxiety or general patient behavior. Any objective 
behavioral measure should have reliability and validity, low bias, be versatile for both 
clinical and laboratory application, and give numbers on an identifiable number scale.46 
One way to minimize bias is called blinding or masking. In blinding the patient, the 
dental operator and the behavior raters are unaware of which treatment group the patient 
is from. 47 A double-blind study is a study in which all three individuals listed above are 
blinded. In order to give a sedation study, reliability raters are calibrated and scales 
standardized against those scales whose reliability is known. These methods are difficult 
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to execute in clinical studies in order to render even simple conclusions. 
Behavior rating scales can be separated into two types, global and restricted 
scales.47 A global scale utilizes a single measure for the overall behavior of a subject for 
the entire appointment. Examples of global rating scales would be the Frankl scale, the 
Visual Analogue Scale (VAS), and the Global Rating Scale. In a 1995 study by Hosey 
and Blinkhom comparing the Frankl scale, the VAS, the Global Rating Scale, and the 
Houpt Scale, the Frankl scale had poor agreement between the raters and should be 
considered an unreliable measure of patient behavior. 48 In another study in 1991 by 
Tafaro et al., the Frankl Scale had less agreement between raters than the North Carolina 
Behavior Rating System (NCBRS).49 The VAS showed low correlation between raters in 
a 1988 study by Parkin. 50 While global scales are simple to use and more practical in a 
clinical setting, they have the disadvantage of being affected subjectively by an extreme 
in behavior for a relatively short period of time by the patient. A restricted scale is a 
measure of specific behaviors that are defmed at either specific milestones, time intervals, 
or continuously. Examples of restricted scales include the Houpt Scale, the NCBRS, and 
the Ohio State University Behavior Rating Scale (OSUBRS). These rating scales have 
the advantage of giving a more complete reflection of the child's behavior throughout the 
sedation and are more sensitive to differences in treatment groups. The disadvantages of 
these scales are that they are more time-consuming for the rater.47 Due to the need for 
extensive recall on the part of the rater, videotaping of the sedation appointment is most 
essential for accuracy. 
While different rating scales can be used to assess a child's behavior, different 
rating time intervals also can be used. The behavior can be rated as a one-time global 
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rating at the end of the sedation, at certain milestones during the course of the sedation 
(i.e. injection, rubber dam placement), at a certain interval of time (i.e. every 15 minutes), 
or continuous rating of the behavior over the course of the entire sedation. A one-time 
global rating of a child's behavior is very subjective, because the child's behavior is rated 
over a time interval that is condensed to a one-time rating. It can be affected by an 
extreme in unsatisfactory behavior that occurred only for a few moments. When the 
behavior is rated at certain milestones during the treatment (local anesthetic injection, 
rubber dam placement), the assessment can also be skewed, because the patient might 
receive stronger stimuli from the particular procedures selected, which can also be close 
in time. Rating a child's behavior in certain time intervals is a consistent means of 
evaluation, but it does not allow for dips in behavior between the rating points. 
Continuous rating of a child's behavior over the course of the entire sedation is the most 
consistent and accurate means to rate a child's behavior. The child's behavior can be 
given a rating based per unit of time, which gives a clear overall picture of the child's 
behavior over the course of the sedation.47 In a 1981 study by Chambers et al., four 
behaviors in non-sedated children were consistent with disruptive behavior. 51 The four 
behaviors were titled as high-hands, leg movements, crying protest, and oral-physical 
resistance. This four-category rating scale is known as the NCBRS or North Carolina 
Behavior Rating Scale. It gives raters of behavior an objective means of rating behavior 
by looking for certain behaviors that are considered disruptive. This helps standardize the 
rating of what is considered bad versus good behavior instead of rating behavior based on 
the individual viewer's opinion. 
Hasty et al. in a 1991 study combined the NCBRS with a computer program 
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(Automated Coding System, version 1.0, JAGTECH, Rockville, MD) to rate videotaped 
behavior of children under sedation with either chloral hydrate, hydroxyzine pamoate, and 
meperidine or chloral hydrate and hydroxyzine pamoate.27 Behavior was rated 
continuously with the computer program coding each change in behavior on a four-point 
behavior category scale and measuring the time during which the behavior was displayed. 
At the end of the sedation, the data were converted into a percentage of total time of the 
sedation for each of the four behavior categories. This allowed for complex statistical 
analysis of the data for a relatively small sample size of 10 children. The findings 
indicated a statistically significant improvement with the addition of meperidine 1.5 
mg/kg. This computer program has been used to rate behavior in at least five studies 
using the OSUBRS.43'44'52 
The use of intramuscular butorphanol (Stadol) may prove to be a viable and 
perhaps ·superior alternative to traditional regimens for sedation of children during dental 
restorative procedures. Butorphanol results in more sedation when compared with 
meperidine and may have fewer side effects than meperidine. In addition, butorphanol 
does not have the abuse and addiction potential associated with Demerol. 
18 
METHODS AND MATERIALS 
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Patients presented to James Whitcomb Riley Hospital for Children Dental Clinic 
were eligible for this study. There was a need for dental restorations and extractions. 
Forty sedations were carried out on eligible children. Only healthy children (American 
Society of Anesthesiology Class 1) between the ages of 13 months and 62 months were 
eligible for participation in this study. A history and physical were completed within 
three months preceding the dental treatment. There was no evidence of enlarged tonsils 
or a history of upper respiratory infection within one month of the planned dental 
sedation. The patient behavior was negative or definitely negative based on the Frankl 
scale (Appendix 1) at the time of the initial dental visit, and the child had failed to 
respo~d to non-pharmacologic behavior modification. An informed written and verbal 
consent was obtained as approved by the Institutional Review Board. 
The parents were given a standard Riley dental sedation protocol (Appendix 2). 
The preoperative instructions were reviewed with the patient's parent at an appointment 
prior to the dental procedure. 
The children selected were randomly assigned to two groups. Group A received 
Demerol (Sanofi Winthrop) 2.0 mg/kg intramuscularly and group B received Stadel 
(Bristol-Myers Squibb Co.) 0.03 mg/kg intramuscularly. The injections were given in the 
upper outer quadrant of the right or left lateral thigh into the V astus Lateralis muscle. In 
this double-blind study, the dentist performing the dental treatlnent, the dentists viewing 
the video (raters), the patients, and the patients' parents were unaware of the treatment 
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group assignment. All patients were monitored using the guidelines established by the 
Academy of Pediatric Dentistry for the elective use of conscious sedation, deep sedation, 
and general anesthesia in pediatric patients.41 A positive pressure oxygen delivery system 
capable of administering 1 00-percent oxygen at a 5 1/min flow was available. A backup 
emergency service was currently set up with an established protocol for immediate 
deployment with the Riley Hospital Department of Anesthesia. An emergency cart 
containing the necessary drugs and equip1nent to resuscitate a non-breathing and 
unconscious patient was in the operatory. 
After 30 minutes, the clinical onset of sedation, the patient was brought back to 
the operatory and placed in a papoose board (Olympic Medical Group, Seattle, W A) with 
the appropriate physiologic monitors: precordial stethoscope and MDE Escort monitor 
(non-invasive blood pressure cuff, pulse rate, ECG, and oxygen saturation) were placed. 
Digital palpation was used to monitor the patient's respiratory rate. The patient received 
supplemental nitrous oxide and oxygen at a concentration not to exceed 50-percent 
nitrous oxide. The dental operator adjusted the flow rate and concentration based on the 
patient's behavior. Following completion of the dental procedure, the patient received 
1 00-percent oxygen for a period of five minutes. Two-percent lidocaine with 1:100,000 
epinephrine was used for local anesthesia not to exceed the cumulative dosage of 4.4 
mg/kg. At any time during the procedure, if the sedation was inadequate, the dental 
treatment was discontinued. Dental treatment consisted of amalgam restorations, resin 
restorations stainless steel crowns, and extractions. Upon completion of the dental 
' 
sedation, the patient was discharged when cardiovascular and airway stability were 
assured, and when the patient was alert and ambulatory. During the recovery period the 
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patient's oxygen saturation was monitored with the pulse oximeter and by visual 
observation. The patient's chart contained documentation that the heart rate, blood 
pressure, color, oxygen saturation, and responsiveness were checked before the 
medication was given (baseline), and during the sedation itself(every 5 minutes), and at 
the time of discharge. The chart also contained the patient's race, gender, age in months, 
weight in kilograms, and all the types and numbers of dental treatment accomplished. 
The MDE escort monitor (Medical Data Electronics, Alerta, CA) utilized in this 
study provided the monitoring of blood pressure, oxygen saturation, ECG, and heart rate 
on a continuous basis. Group A and B were evaluated for any statistically significant 
changes in these physiologic parameters. 
All sedation appointments were videotaped using a VHS video camera. Taping 
commenced from the time the patient was brought into the operatory to begin the 
operative· treatment until the patient was dismissed into the recovery room after operative 
treatment. The view of the videotapes included the patient's entire body filmed 
consistently from the same position in the treatment room. The videotapes of the 
sedation were reviewed by three observers independently to achieve an objective 
behavioral assessment of the dental sedation. 
The ACS or Automated Coding System (Version 1.0, JAGTECH, Rockville, MD 
1987) was used by the observers as an assessment tool of the child's behavior on a 
chronologically continuous basis. The observers that watched the sedation pressed one of 
four buttons (Appendix 3) depending on the patient's behavior. The modified NCBRS, 
as described by Hasty et al. in 1991,27 was used to look at the four undesirable behaviors 
of foot movement, torso movement, head movement, and crying. This behavior rating 
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scale begins with the most desirable behavior rating of Quiet, proceeds to Annoyed, then 
to Upset, and ends with the most undesirable behavior rating of Zoo. At the end of the 
sedation the coding session was stored and processed using the same program. The 
results of the program data analysis revealed total time of sedation, total time spent in 
each behavior category, the minimum and maximum time spent in each behavior 
category, and the number of occurrences of each behavior category type. 
Another assessment tool used to evaluate the dental sedation was the categorical 
scale that evaluates crying, apprehension, cooperation, and sleep, which is useful when 
comparing different drugs where qualitative and quantitative drug effects are being 
evaluated. Using this categorical scale (Appendix 4) the patient's behavior was evaluated 
five times during the procedure: immediately prior to beginning of operative treatment, 
during local anesthetic administration, during rubber dam placement, during cavity 
placement, ~nd during carving of the restoration. 
A second scale, the dichotomous scale (Appendix 5) developed by Moore et al./3 
was also used for this study. This scale was based on the presence or absence of a 
behavior and eliminates the quantification, which can be interpreted differently from one 
observer to another. It has high inter-rater reliability and is useful when assessing the 
safety of pharmacologic agents. 
Lastly, the dentist performing the restorative treatment and administering the 
medication rated the sedation using the dichotomous scale, sedation success and a global 
rating scale (Appendix 6). This rating can be compared with the independent raters 
evaluation to note the differences between the perceptions of the operator and outside 
independent raters. Operators evaluated the airway status of each patient by tilting the 
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patient's chin towards the patient's chest and checking to see if the patient maintained his 
or her airway independently once the head was released. 
STATISTICAL ANALYSIS 
One-way ANOV A models were used to compare group A and group B for 
differences in baseline means for the physiologic parameters (systolic and diastolic blood 
pressure, oxygen saturation, heart rate, and respiration rate) using repeated measures 
analysis of variance. Analysis of covariance (AN COY A) models were used to compare 
group A and group B for differences in means during treatment for the physiological 
parameters by using the baseline parameters as covariates. One-way ANOV A models 
were also used to compare group A and group B for differences in means during 
treatment for the physiological parameters. Fisher's Exact tests were used to compare the 
patients U: group A and group B for differences in race and gender and in the percentages 
of patients· receiving stainless steel crowns, resin restorations, amalgam restorations, or 
extractions. One-way analysis of variance (ANOV A) models were used to compare the 
patients in group A and group B for differences in mean age (in months) and weight (in 
kilograms). 
ACS ratings for groups A and B were compared for differences in total sedation 
time, total number of code changes, time to behavior change, and percentage of time 
spent in each behavior category using analysis of variance (ANOVA) models with subject 
and viewer as random effects and group as a fixed effect. The analyses for the percentage 
of time spent in each behavior category were made after using a variance-stabilizing 
transformation (arcsine-square root percentage). The three independent viewers' ratings 
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of Group A and group B were compared for differences in sedation in operatory, sedation 
in operatory with nitrous oxide, and reaction to injection by using generalized estimating 
equation (GEE) methods applied to logistic regression. GEE methods were necessary to 
correlate the ratings by multiple viewers on the same subject. Group A and group B were 
also compared for differences in global rating scale, crying, cooperation, apprehension, 
and sleep by using GEE methods applied to cumulative logistic regression. 
Fisher's Exact tests were used to compare the operator's ratings for group A and 
group B for differences in pre- and post-treatment Frankl, sedation in quiet room, 
sedation in operatory, sedation in operatory with nitrous oxide, and reaction to injection. 
Cochran-Mantel-Haenszel tests for ordinal data were used to compare group A and group 
B for differences in sedation success and global ratings of the operator. 
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RESULTS 
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The meperidine and butorphanol groups did not have statistically significant 
different mean age (p = 0.6947) or weight (p = 0.3676) (Table I). 
The meperidine and butorphanol groups did not show a statistically significant 
different percentage between race (p = 1.000) or gender (p = 0.748) in the patient groups 
(Table II). Forty percent of the meperidine and butorphanol groups' patients were 
caucasian and 60 percent were non-white respectively. The meperidine and butorphanol 
groups did not have statistically significant different percentage of stainless steel crowns 
(p = 1.000), resin restorations (p = 1.000), or amalgam restorations (p = 0.605) (Table II). 
There was slight evidence of more patients with extractions (p = 0.054) in the 
butorphanol group than in the meperidine group (Table II). 
The meperidine and butorphanol groups did not have significantly different mean 
pulse (p = 0.1616), systolic blood pressure (p = 0.2691), diastolic blood pressure 
(p = 0.8831), respiration rate (p = 0.7471), or oxygen saturation (p = 0.5473) at baseline 
(Table III). One patient was missing baseline pulse and one patient was missing baseline 
diastolic blood pressure. Sixteen of the 40 patients had an oxygen saturation 
measurement at baseline. 
Four patients were missing systolic blood pressure data during treatment. Fifteen 
patients were missing diastolic blood pressure data during treatment. Twelve patients 
were missing respiration rate data during treatment. All patients in both groups had an 
electrocardiogram that stayed at normal sinus rhythm from baseline and throughout 
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treatment. For the physiologic parameters recorded, the meperidine and butorphanol 
groups did not have significantly different mean pulse (p = 0.2917), systolic blood 
pressure (p = 0.4776), diastolic blood pressure (p = 0.2217), or respiration rate 
(p = 0.5745) during treatment (Table IV). The meperidine group had a higher mean 
oxygen saturation during treatment than the butorphanol group. 
The meperidine and butorphanol groups were not statistically significantly 
different when total sedation time was compared (p = 0.2058) (Table V). The mean total 
sedation tim~ of the meperidine group was 3535.38 sec while the butorphanol group's 
mean time was 3111.13 sec. 
The two groups were not statistically significantly different when the total number 
of code changes were compared (p = 0.4356) (Table VI) and were not statistically 
significantly different when time to behavior change was analyzed (p = 0.2111) (Table 
Vll). 
The groups did not spend a statistically significant different percentage of time in 
the Upset (p = 0.45) or Zoo (p = 0.60) categories respectively. The butorphanol group 
spent significantly more time in the annoyed category (p = 0.0238) and showed a trend 
toward less time spent in the quiet category (p = 0.0886) (Table VIII). 
The groups' sedation in opera tory ratings were not statistically significantly 
different (p = 1.0000) (Table IX). 
The groups' sedation in operatory with nitrous oxide ratings were not statistically 
significantly different (p = 0.7076) (Table X). 
The groups' reaction to injection ratings were not significantly different 
(p = 0.0630) (Table XI). 
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The groups' global scale ratings were not statistically significantly different 
(p = 0.2909) (Table Xll). 
The groups' crying ratings were not statistically significantly different (p = 
0.0685) (Table Xill). 
The groups' cooperation ratings were not statistically significantly different 
(p = 0.21 00) (Table XIV). 
The groups' apprehension ratings were not statistically significantly different 
(p = 0.2139) (Table XV). 
The groups' sleep ratings were not statistically significantly different (p = 0.2533) 
(Table XVI). 
The meperidine and butorphanol groups did not have statistically significantly 
different pre- (p = 0.741) and post-treatment Frankl (p = 0.751), sedation in quiet room 
(p = 1.000), sedation in opera tory (p = 0.191 ), sedation in operatory with nitrous oxide 
(p=0.320), and reaction to injection ratings from the operator (p = 0.517) (Table XVIT). 
The meperidine and butorphanol groups did not have statistically significant 
different sedation success ratings of the operator (p = 0.146). There was some evidence 
that the meperidine group had a statistically significant better global rating than the 
butorphanol group (p = 0.072) (Table XVill). 
Four of the subjects had 2 sedations, so that they were given one medication each 
time. All of the patients in both groups had their airway rating as clear in both the 
operatory and in opera tory with nitrous oxide. No oxygen desaturations ( <96-percent 
oxygen saturation) were noted with either group. No immediate perioperative 
complications were noted with either group. 
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FIGURES AND TABLES 
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TABLE I 
Age (months) and weight (kilograms) of the meperidine 
and butorphanol groups 
Age (Months) Weight (Kilograms) 
Group Mean Standard Deviation Mean Standard Deviation 
A (Meperidine) 34.60 10.96 15.20 2.53 
B (Butorphanol) 33.40 8.01 14.49 2.43 
p-value 0.6947 0.3676 
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TABLE II 
Fisher's Exact test results for race and gender and the 
percentages of patients receiving stainless steel crowns, 
resin restorations, amalgam restorations, and extractions 
A (Meperidine) B (Butorphanol) 
Category Response # percent # percent p-value 
Race White 8 40 8 40 
Non-white 12 60 12 60 
Gender Female 9 45 7 35 
Male 11 55 13 65 
Stainless Steel Crowns Yes 10 50 9 45 
No 10 50 11 55 
Resin Restorations Yes 16 80 16 80 
No 4 20 4 20 
(continued) 
1.000 
0.748 
1.000 
1.000 
Amalgam 
Extractions 
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(continued) 
TABLE IT 
Fisher's Exact test results for race and gender and the 
percentages of patients receiving stainless steel crowns, 
resin restorations, amalgam restorations, and extractions 
Yes 3 15 1 5 
No 17 85 19 95 
Yes 5 25 12 60 
No 15 75 8 40 
0.605 
0.054 
Physiologic Sign 
Pulse 
Systolic B.P. 
Diastolic B.P. 
Respiration Rate 
Oxygen Saturation 
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TABLE III 
Baseline means for the physiological parameters 
and one-way ANOV A analysis results 
Meperidine Butorphanol 
Mean Standard Deviation Mean Standard Deviation 
105.53 14.80 112.60 16.06 
91.85 16.77 97.35 14.13 
57.26 10.22 57.75 10.31 
24.25 4.77 24.65 2.76 
99.67 0.52 99.50 0.53 
p-value 
0.1616 
0.2691 
0.8831 
0.7471 
0.5473 
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TABLEN 
ANCOV A analysis of comparing means during treatment 
for physiological parameters using the baseline parameters 
as covariates* 
Meperidine Butorphanol 
Vital Signs Mean S.D. Mean S.D. ANOVA 
Pulse 125.67 28.40 132.95 21.76 0.3686 
Systolic B.P. 103.52 16.53 100.34 10.14 0.4917 
Diastolic B.P. 58.82 11.83 64.00 8.34 0.2152 
Resp. Rate 25.14 2.64 25.86 3.34 0.5280 
Oxygen Sat. 99.63 0.48 99.20 0.56 0.0116 
p-value 
ANCOVA 
0.2917 
0.4776 
0.2217 
0.5745 
0.0806 
* One-way ANOV A analysis to compare the groups for differences in means during treatment for the 
physiological parameters because of missing baseline data. 
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TABLEV 
Total sedation time 
Viewer 1 
Group # Mean S.D. S.E. Minimum Maximum 
B 20 3124.60 967.63 216.37 1067.00 5756.00 
A 20 3543.95 1130.86 252.87 407.00 5442.00 
Viewer 2 
Group # Mean S.D. S.E. Minimum Maximum 
B 20 3137.95 967.32 216.30 1126.00 5800.00 
A 20 3550.00 1139.67 254.84 388.00 5475.00 
\ 
Viewer 3 
Group # Mean S.D. S.E. Minimum Maximum 
B 20 3070.85 980.68 219.29 1314.00 5758.00 
A 20 3512.20 1147.12 256.50 403.00 5438.00 
(continued) 
Group # 
B 
A 
20 
20 
Mean 
3111.13 
3535.38 
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(continued) 
TABLEV 
Total sedation time 
S.D. 
957.75 
1137.63 
Average 
S.E. 
214.16 
254.38 
Minimum 
1169.00 
399.33 
Maximum 
5771.33 
5445.00 
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TABLE VI 
Total number of code changes 
ViewerGroup # Mean S.D. S.E. Minimum Maximum 
1 
2 
3 
Average 
B 
A 
B 
A 
B 
A 
20 
20 
20 
20 
20 
20 
B 20 
A · 20 
29.40 20.16 4.51 2.00 
23.70 19.93 4.46 2.00 
28.15 20.02 4.48 4.00 
22.25 19.95 4.46 2.00 
77.05 43 .32 9.69 13.00 
68.55 55.07 12.32 5.00 
44.87 24.36 5.45 7.00 
38.17 29.47 6.59 3.00 
63.00 
81.00 
75.00 
80.00 
157.00 
193.00 
98.00 
109.67 
Group # Mean 
B 20 246.18 
A 20 316.85 
Group # 
B 
A 
20 
20 
Group # 
B 
A 
20 
20 
Mean 
208.50 
396:47 
Mean 
71.63 
130.92 
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TABLE VII 
Time to behavior change 
S.D. 
401.14 
335.67 
S.D. 
232.66 
463.86 
S.D. 
79.35 
159.28 
Viewer 1 
S.E. 
89.70 
75.06 
Viewer 2 
S.E. 
52.02 
103.72 
Viewer 3 
S.E. 
17.74 
35.62 
(continued) 
Minimum 
45.55 
37.00 
Minimum 
37.97 
47.90 
Minimum 
17.25 
18.08 
Maximum 
1865.50 
1365.50 
Maximum 
935.75 
1561.50 
Maximum 
250.31 
547.00 
Group # 
B 
A 
20 
20 
Mean 
175.44 
281.41 
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(continued) 
TABLE VII 
Time to behavior change 
S.D. 
225.78 
300.51 
Average 
S.E. 
50.49 
67.20 
Minimum 
33.91 
44.60 
Maximum 
1016.82 
1093.67 
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TABLE VIll 
Percentage of time spent in each behavior 
category (code) as rated by the 3 viewers 
ViewerGroup # Mean S.D. S.E. Minimum 
1 B quiet 20 34.44 30.32 6.78 0.00 
* annyd 20 26.63 22.69 5.07 0.00 
upset 20 20.07 17.60 3.93 0.00 
zoo 20 18.87 28.15 6.29 0.00 
A quiet 20 52.86 34.98 7.82 0.00 
annyd 20 15.54 11.01 2.46 0.20 
upset 20 19.34 21.86 4.89 0.00 
' zoo 20 12.28 22.65 5.07 0.00 
2 B quiet 20 32.34 29.77 6.66 0.50 
annyd 20 35.58 26.49 5.92 0.70 
upset 20 13.06 11.43 2.56 0.00 
zoo 20 17.91 24.61 5.50 0.00 
A quiet 20 52.45 36.30 8.12 0.00 
(continued) 
Maximum 
90.00 
91.00 
61.90 
95.50 
99.80 
32.90 
77.20 
88.00 
90.40 
88.70 
35.70 
88.40 
99.20 
3 B 
A 
Ave B 
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(continued) 
TABLE VIII 
Percentage of time spent in each behavior 
category (code) as rated by the 3 viewers 
annyd 20 17.16 15.63 3.49 0.80 
upset 20 13.60 17.41 3.89 0.00 
zoo 20 16.54 24.68 5.52 0.00 
quiet 20 40.56 27.72 6.20 0.00 
annyd 20 30.04 22.36 5.00 0.00 
upset 20 15.34 10.07 2.25 0.00 
zoo 20 14.02 22.32 4.99 0.00 
quiet 20 54.98 31.93 7.14 0.50 
annyd 20 21.11 17.17 3.84 0.30 
upset 20 10.43 10.77 2.41 0.00 
zoo 20 13.38 20.95 4.69 0.00 
quiet 20 35.78 28.85 6.45 0.77 
annyd 20 30.75 21.70 4.85 0.23 
(continued) 
* annoyd = annoyed 
50.30 
53.20 
94.10 
90.70 
92.70 
33.70 
87.70 
99.70 
71.70 
35.00 
77.70 
90.37 
90.80 
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(continued) 
TABLE VIII 
Percentage of time spent in each behavior 
category (code) as rated by the 3 viewers 
upset 20 16.16 10.78 2.41 0.00 36.93 
zoo 20 16.93 22.65 5.06 0.00 87.20 
A quiet 20 53.43 33.33 7.45 0.17 99.57 
annyd 20 17.93 11.66 2.61 0.43 38.20 
upset 20 14.45 15.97 3.57 0.00 48.90 
zoo 20 14.06 22.27 4.98 0.00 86.60 
Viewer 
1 
2 
3 
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TABLE IX 
Sedation in operatory rating by the 3 viewers 
Group Satisfactory Unsatisfactory 
Butorphanol 12 8 
Meperidine 13 7 
Butorphanol 8 10 
Meperidine 8 10 
Butorphanol 12 8 
Meperidine 11 9 
Viewer 
1 
2 
3 
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TABLE X 
Sedation in operatory with nitrous oxide rating by the 3 viewers 
Group Satisfactory Unsatisfactory 
Butorphanol 13 7 
Meperidine 13 7 
Butorphanol 8 11 
Meperidine 9 10 
Butorphanol 11 8 
Meperidine 12 7 
Viewer 
1 
2 
3 
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TABLE XI 
Reaction to injection rating by the 3 viewers 
Group Satisfactory 
Butorphanol 10 
Meperidine 14 
Butorphanol 11 
Meperidine 14 
Butorphanol 10 
Meperidine 12 
Unsatisfactory 
9 
5 
8 
5 
10 
7 
Viewer 
1 
2 
3 
Group 
B 
A 
B 
A 
B 
A 
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TABLE XII 
Global scale ratings as rated by the 3 viewers 
Poor Fair Good Very Good Excellent 
7 
6 
9 
7 
5 
6 
1 
1 
5 
3 
6 
3 
6 
1 
3 
3 
5 
6 
3 
4 
0 
1 
3 
2 
3 
8 
3 
6 
1 
3 
Viewer 
1 
2 
3 
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TABLE XIII 
Crying ratings as rated by the 3 viewers 
Group Screaming Continuous Mild 
Butorphanol 4 5 10 
Meperidine 3 1 8 
Butorphanol 6 8 4 
Meperidine 5 5 5 
Butorphanol 2 7 11 
Meperidine 2 5 9 
None 
1 
8 
2 
5 
0 
4 
Viewer 
1 
2 
3 
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TABLEXN 
Cooperation ratings as rated by the 3 viewers 
Group Resistant Difficult Minor 
Butorphanol 4 4 10 
Meperidine 3 4 5 
Butorphanol 2 9 6 
Meperidine 5 4 5 
Butorphanol 1 11 8 
Meperidine 2 6 9 
None 
2 
8 
3 
6 
0 
3 
Viewer 
1 
2 
3 
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TABLE XV 
Apprehension ratings as rated by the 3 viewers 
Group Hysterical Anxious Mild 
Butorphanol 4 3 10 
Meperidine 2 5 4 
Butorphanol 6 6 6 
Meperidine 7 3 4 
Butorphanol 3 3 14 
Meperidine 2 4 11 
Calm 
3 
9 
2 
6 
0 
3 
Viewer 
1 
2 
3 
50 
TABLE XVI 
Sleep ratings as rated by the 3 viewers 
Group Awake Drowsy Intermittent Asleep 
Butorphanol 3 8 7 2 
Meperidine 4 2 8 6 
Butorphanol 9 4 5 2 
Meperidine 8 2 5 5 
Butorphanol 6 5 9 0 
Meperidine 4 3 11 2 
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TABLE XVII 
Operator's dichotomous scale ratings of the sedation and 
the Fisher's Exact test analysis of statistical significance 
Meperidine Butorphanol 
Observations Scale # percent # percent p-value 
Pre-treatment Frankl Satisfactory 14 70 12 60 0.741 
Unsatisfactory 6 30 8 40 
Post-treatment Frankl Satisfactory 10 50 8 40 0.751 
Unsatisfactory 1 0 50 12 60 
Sedation in Quiet Room Satisfactory 15 75 15 75 1.000 
Unsatisfactory 5 25 5 25 
Sedation in Operatoiy Satisfactory 10 50 5 25 0.191 
Unsatisfactory 10 50 15 75 
Sedation in Operatory Satisfactory 15 75 11 58 0.320 
with Nitrous Oxide 
Unsatisfactory 5 25 8 42 
Reaction to Injection Satisfactory 11 58 8 42 0.517 
Unsatisfactory 8 42 11 58 
Observations 
Sedation Success 
Global Rating 
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TABLE XVIII 
Operator's sedation success and global scale 
ratings and the results of the Cochran-Mantel-Haenszel 
tests for ordinal data 
Meperidine Butorphanol 
Scale # percent # percent p-value 
Unsuccessful 1 5 1 5 0.146 
Poor 4 20 5 25 
Fair 3 15 6 30 
Good 4 20 5 25 
Very Good 0 0 0 0 
Excellent 8 40 3 15 
Poor 2 10 1 5 0.072 
Fair 3 15 9 45 
Good 5 25 5 25 
Very Good 2 10 3 15 
Excellent 8 40 2 10 
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DISCUSSION 
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Thirty-six patients between the ages of 20 and 62 months participated in this 
study. The patient groups were equally matched for race and gender (meperidine group 
was 45 percent female and 55 percent male while the butorphanol group was 35 percent 
female and 65 percent male). The restorative treatment was similar in both groups. There 
were slightly more extractions in the butorphanol group. 
The physiologic parameters that were examined are as follows: blood pressure, 
oxygen saturation, heart rate, and respiration rate. There was no statistical difference 
between any of the physiologic data between the meperidine and butorphanol groups, 
although the meperidine group had a slightly higher mean oxygen saturation rate during 
treatment of99.63 p'ercent compared with the butorphanol group's mean of99.20 percent. 
This slightly higher oxygen saturation difference of 0.43 percent for the meperidine 
group was not clinically significant. Hasty et al. in a 1991 sedation study did not consider 
a pulse oximeter reading a desaturation unless it was below 96-percent oxygen 
saturation27 (in fact, both the meperidine and butorphanol groups exhibited mean baseline 
and mean treatment pulse oximeter ratings greater than 99 percent, which is well above 
96 percent). None of the subjects in either group had any desaturation episodes during 
treatment. Unreported physiologic data occurred due to patient movement (automatic 
blood pressure cuff and pulse oximeter) and crying (respiration rate). Unreported data 
may be unavoidable because of the uncooperative behavior of the patient pool. Overall, 
no adverse reactions occurred and all vital signs were within normal ranges before, 
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during, and after treatment. 
Many of the meperidine subjects exhibited pruritis seen as itching of the nose (not 
a planned observation, but a known side effect of meperidine). No actual record of the 
number of occurances or severity ofpruritis was made. Butorphanol subjects showed no 
signs of pruritis. 
The butorphanol group's ACS ratings' tendency to spend more percentage of time 
in the annoyed rating and less time in the quiet rating offers little clinical difference from 
the meperidine group. These ratings are next to each other on the 4 point rating scale and 
the difference between a quiet and annoyed rating is not much when compared to the 
difference between a quiet and zoo rating (at opposite ends of the rating scale). Perhaps a 
dichotomous scale, or a 2 point behavior rating scale would be more useful in 
differentiating between the absolute poor and good behaviors by limiting the viewers to 
one of two choices .' 
The three trained pediatric dentist viewers showed no statistically significant 
difference between the categorical scale (Table XIII, XIV, XV, XVI), the dichotomous 
scale (Table IX, X, XI XII), and the global rating scale (Table XII) when the butorphanol 
and meperidine groups. This shows that the two groups grossly did not differ in the 
various behavior rating scales in the mind of the viewers. 
Four subjects in each group were repeat subjects. The statistical analysis 
tabulated them as if they were independent subjects. Whether or not these subjects are 
analyzed as independent or repeat subjects makes no difference on the dichotomous, 
categorical, and global rating scales. On the ACS ratings when the subjects are treated as 
repeat subjects, the meperidine group appears to have better results. It happens that these 
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four subjects did much better with meperidine than they did with butorphanol. These 
were only four subjects out of a group of20. It was decided to treat these subjects as 
independent subjects, because these four subjects should not cause a shift in the results. 
There was no statistically significant difference between the groups in regards to 
the sedation success rating, but the operators rated the meperidine group with a better 
global rating than the butorphanol group. 
Overall, butorphanol was not superior to meperidine in regards to physiologic or 
patient behavior effects, but had similar results to meperidine. Neither medication had 
any adverse events associated with it. 
While both groups were effective with some patients as a sedative medication, 
both groups were not effective 100 percent of the time. An addition of a promethazine or 
another co sedative may help the effectiveness of both drugs. If no increase in physiologic 
effects, an increase ih butorphanol dosage may help with potential sedation success. 
WEAKNESSES IN STUDY DESIGN OR METHOD USED 
One weakness in the study design was the inconsistency of using some subjects in 
both groups and others in only the experimental group or the control group. There is no 
way to determine what effect the first sedation may have had on the outcome of the 
second sedation, in those patients who were treated as subjects in both groups. While, 
this inconsistency casts a shadow of doubt on the reliability of the results, this problem 
was minimized by blinding the viewers and the operators to the sedative agents being 
used at each patient visit. 
A second weakness of the study was the use of multiple operators. Multiple 
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operators probably did not have a significant effect on the outcome of this study, because 
it was designed to compare medications instead of behavior management techniques. 
A third weakness of study is the inclusion of nitrous oxide analgesia in addition to 
the sedation medication. This should have little effect on telling the effectiveness of the 
experimental medication versus the control medication, because it was used with both 
groups; however, it could be difficult to tell the true effectiveness of either medication by 
itself. Clinically, most sedations in dentistry are carried out with nitrous oxide analgesia 
in addition to any sedation medication, so that this aspect of study design could prove to 
be more applicable to the "real world" sedation situation. 
Considerable physiologic data that should have been recorded by the pulse 
oximeter and the automatic blood pressure recorder are missing. These missing 
recordings were unavoidable, because some patients' behaviors disengaged the terminal 
connectors of the .instruments. The missing recordings prevented the collection of 
complete data, but had no adverse effect on the patients or their therapies. 
SUGGESTIONS FOR FUTURE STUDIES 
This was the first study to examine the use ofbutorphanol as a sedative 
medication in pediatric dental patients. The dosage was determined by the dosages in 
previously mentioned studies. The dosage selected was a safe level based on these 
studies. The encouraging results of this study should justify the opportunity for further 
study ofbutorphanol for sedation in pediatric dentistry. 
A similar study to this one should be completed in the future involving three 
different intramuscular dosage levels ofbutorphanol against the same control dosage of 
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meperidine (2.0 mg/kg) . The study should involve the use of the same operator 
throughout. There should be a minimum of30 subjects in each group. 
Following this, a similar second follow-up study should be attempted using the 
superior intramuscular dosage ofbutorphanol and to compare it with and without a co-
sedative. These groups would again be compared with a control sedative of meperidine. 
Finally, a similar future study should be made using several oral dosages of 
butorphanol compared with the superior intramuscular butorphanol dosage. 
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SUMMARY AND CONCLUSIONS 
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Treating pediatric dental patients who are four years old and younger can be 
difficult at times due to patient behavior. Conscious sedation has been employed as a 
means to control pediatric dental patients for several years. All sedative medications 
have undesirable side effects. Meperidine has been a favored sedative for conscious 
sedation in pediatric dental patients. The purpose of this study is to compare the 
behavioral and physiologic effects of conscious sedation on pediatric dental patients using 
intramuscular meperidine and an equipotent dosage of intramuscular butorphanol. The 
hypothesis of the thesis is that when intramuscular butorphanol is compared with 
intramuscular meperidine in an equipotent dosage for sedation of pediatric dental 
patients, butorphahol will have equal or better quality of level of sedation while 
displaying equal or less physiological effects on the patient. 
Forty conscious sedations of 36 A.S.A. I pediatric dental patients between the 
ages of 13 and 60 months were accomplished using either 2.0 mg/kg of intramuscular 
meperidine or 0.03 mg/kg of intramuscular butorphanol. Each sedation was videotaped, 
and three viewers studied the videotapes rating them with a computer program (ACS) 
involving a four-code behavior rating scale. The three viewers rated patient behavior for 
each sedation also with a form with global rating, categorical, and dichotomous scales. 
Physiologic signs of oxygen saturation, blood pressure, heart rate, and respiration rate 
were monitored at baseline and every 5 minutes during treatment. The operator also rated 
the sedation patient behavior with a form that had pre-treatment Frankl, post-treatment 
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Frankl, global rating categorical, dichotomous, and sedation success rating scales. The 
two groups' treatment data, physiologic data, ACS data, the three viewer's behavior 
rating form, and the operator's behavior rating form were analyzed for any statistically 
significant differences between the groups. 
The statistical analysis of the treatment data revealed a statistically significant 
dental treatment trend in the butorphanol group toward extractions (p = 0.054). The 
meperidine group had a mean oxygen saturation of99.63 percent during treatment, and 
this was statistically significant (p = 0.0806) when compared with the butorphanol 
group's mean oxygen saturation of 99.20 percent. This was well above the safe level of 
desaturation of 96-percent oxygen saturation. The difference between the meperidine 
group's and the butorphanol group's mean oxygen saturation was clinically insignificant. 
The butorphanol group spent significantly more time in the annoyed ACS behavior rating 
code (p = 0.0886)' and showed a trend toward less time spent in the quiet ACS behavior 
rating code. This trend in the butorphanol group toward more time in the annoyed ACS 
behavior rating code and less time spent in the quiet ACS behavior rating code is not 
clinically significant, due to the subjectivity of a four-point rating scale. There were no 
statistically significant differences in the three viewers' ratings of global rating, 
categorical, and dichotomous scales. The operators' ratings showed the meperidine group 
had a statistically significant better global rating than the butorphanol group (p = 0.072). 
This finding shows that the operators rated the meperidine group as a better sedation 
agent in a global sense. 
The overall success of sedation with butorphanol rated with the ACS rating scale 
appears to be equal to meperidine in the lack of physiologic side effects and patient 
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behavior effects. There was minimal physiological impact on the physiologic parameters 
measured with both medications. No adverse effects occurred with either medication. 
Intramuscular butorphanol at the dosage of0.03 mg/kg may be offered as a safe 
alternative sedative agent to other narcotic sedative agents with more side effects. 
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APPENDIX 
Frankl behavior rating scale 
Refusal of treatment; crying 
forcefully, fearful, extreme 
negativism 
Reluctant, uncooperative, limited 
negativism, sullen, withdrawn 
Accepts treatment but may be 
cautious or reserved, follows 
directions 
Good rapport, interested in dental 
procedures, laughs and enjoys 
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APPENDIX 1 
Wright modification 
Definitely negative 
Negative 
Positive 
Defmitely positive 
Dear Parent: 
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APPENDIX2 
Pre-Sedation Instructions 
In our recent discussion about your child's up-coming dental treatment, we have 
agreed that it will be necessary to premedicate your child. This premedication will help 
us to provide the best possible dental treatment in a well-controlled setting. In order to 
accomplish this safely with the best chance for success, there are certain procedures we 
ask that you follow before and after the appointment. These are as follows: 
1. A child is much influenced by his/her parents' behavior. If you are anxious, upset, and 
worried about going to the dentist, so will be your child. Please relax. 
2. Your child should have a good night's rest before each appointment. 
3. Your child should have nothing to eat for at least 6 hours before the appointment. 
Small amounts of clear liquids are permissible up to 4 hours before the appointment. 
4. As legal guardian you must accompany your child. 
5. It is very important that your child be in good health for this appointment. Please 
advise us of the presence of a cold, cough, runny nose, or fever when your appointment is 
confirmed. Sedation will not be administered when a child is ill. 
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6. Your child will not be put to sleep, only "relaxed". At times he/she may fall asleep, 
but can be aroused. 
7. Because of the tendency towards drowsiness and clumsiness for several hours, your 
child should remain indoors and be closely watched for several hours after the 
appointment. 
8. It is normal for the child to sleep after the appointment. 
9. In case you have any questions once you are home, call Riley Dental Clinic. 
Automated Coding System 
Code 
Q =quiet 
A= annoyed 
U =upset 
Z=zoo 
73 
APPENDIX3 
Behavior Criteria 
Patient quiet and/or asleep with only extraneous, 
inconsequential movements. 
Patient cooperative allowing treatment to proceed 
easily, but with one to two undesirable behaviors 
present. 
Patient noticeably disturbed, with two to three 
undesirable behaviors present, making treatment 
difficult, but possible. 
Patient extremely defiant with presence of foot 
movement, torso movement, head movement, and 
crying to the extent that treatment was difficult or 
impossible. 
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APPENDIX4 
0 
Categorical Rating Scale 
Crying 
1 = Screaming 
2= Continuous Crying 
3= Mild, Intermittent Crying 
4=No Crying 
Cooperation 
1 = Violently Resists/Disrupts Treatment 
2= Movements which make treatment difficult 
3= Minor Movement/Intermittent 
4= No Movement 
Apprehension 
1 =Hysterical/Disobeys all instructions 
2= Extremely anxious/Disobeys some/Delays treatment 
3= Mildly anxious/Complies with support 
4= Calm/Relaxed/Follows instructions 
(continued) 
Sleep 
1 = Fully awake 
2=Drowsy 
3= Asleep/Intermittent 
4= Sound asleep 
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(continued) 
APPENDIX4 
Dichotomous Scale 
A Sedation behavior in operatory 
B Airway maneuver in operatory 
C Sedation behavior in operatory 
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APPENDIX 5 
Satisfactory 
Clear 
Satisfactory 
D Airway maneuver with nitrous oxide Clear 
E Reaction to injection Satisfactory 
Unsatisfactory 
Obstructed 
Unsatisfactory 
Obstructed 
Unsatisfactory 
Sedation Success 
Unsuccessful 
Poor 
Fair 
Good 
Very Good 
Excellent 
Global Rating 
Poor 
Fair 
Good 
Very Good 
Excellent 
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APPENDIX 6 
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CONSCIOUS SEDATION OF THE PEDIATRIC DENTAL PATIENT: 
A COMP ARlSON OF MEPERIDINE VERSUS BUTORPHANOL 
by 
Andrew C. Guthrie 
Indiana University School of Dentistry 
Indianapolis, Indiana 
Treating pediatric dental patients four years old and younger can be difficult at 
times due to patient behavior. Conscious sedation has been employed as a means to 
control pediatric dental patients for several years. Butorphanol tartrate has been used 
safely for pain control in pediatric patients for several years, but has never been used for 
sedating pediatric dental patients. The purpose of this study is to compare the behavioral 
and physiologic effects of conscious sedation on pediatric dental patients using 
intramuscular meperidine and an equipotent dosage of intramuscular butorphanol. Forty 
conscious sedations of ASA I pediatric dental patients between the ages of 13 and 60 
months were accomplished using either 2.0 mglkg of intramuscular meperidine or 0.03 
mg/kg of intramuscular butorphanol. Each sedation was videotaped and three viewers 
viewed the videotapes rating them with a computer program (ACS) involving a four-code 
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behavior rating scale. The tlrree viewers rated patient behavior for each sedation also 
with a form with global rating, categorical, and dichotomous scales. Physiologic signs of 
oxygen saturation, blood pressure, heart rate, and respiration rate were monitored at 
baseline and every 5 minutes during treatment. The operator also rated the sedation 
patient behavior with a form that had pre-treatment Frankl, post-treatment Frankl, global 
rating categorical, dichotomous, and sedation success rating scales. The two groups 
demographic data, physiologic data, ACS data, the tlrree viewer's behavior rating form, 
and the operator's behavior rating form were analyzed for any statistically significant 
differences between the groups. The statistical analysis of the demographic data revealed 
a statistically significant trend in the butorphanol group toward extractions. The 
meperidine group had a statistically significant higher mean oxygen saturation during 
treatment (99.63 percent) than the butorphanol group (99.20 percent). The butorphanol 
group spent significantly more time in the annoyed ACS behavior rating code and showed 
a trend toward less time spent in the quiet ACS behavior rating code. There were no 
statistically significant differences in the tlrree viewers ratings of global rating, 
categorical, and dichotomous scales. The operators' ratings showed the meperidine group 
had a statistically significant better global rating than the butorphanol group. Overall 
butorphanol appears to be equal clinically to meperidine in physiologic effects and patient 
behavior effects. No adverse effects occurred with either medication. Butorphanol may 
be offered as an alternative sedative agent to other narcotic sedative agents with more side 
effects. 
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